<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184977</url>
  </required_header>
  <id_info>
    <org_study_id>98-46140</org_study_id>
    <secondary_id>95093 FLU9802 NAC-NL-11</secondary_id>
    <nct_id>NCT00184977</nct_id>
  </id_info>
  <brief_title>COPD on Primary Care Treatment (COOPT)</brief_title>
  <official_title>A Double-blind Placebo-controlled Trial Comparing the Efficacy and Cost-effectiveness of Inhaled Fluticason Propionate Versus Oral N-acetylcysteine in the Treatment of Patients With COPD in General Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Health Care Insurance Board (CVZ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Asthma Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The aim of this family practice based study is to determine the long-term treatment effects&#xD;
      of two drugs that are presumed to modify the course and progression of chronic obstructive&#xD;
      pulmonary disease (COPD), oral N-acetylcysteine and inhaled corticosteroids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is a disorder characterised by symptoms and&#xD;
      abnormal tests of expiratory flow that do not change markedly over periods of several months&#xD;
      observation. COPD includes chronic bronchitis and emphysema. It is not fully clear which&#xD;
      medication is the most efficacious in the long-term treatment of COPD. In contrast to asthma,&#xD;
      the efficacy and therefore the precise role of inhaled corticosteroids is less clear in the&#xD;
      treatment of patients with COPD. The same applies to another (much less investigated)&#xD;
      possibility in the treatment of COPD, the anti-oxidant agent N-acetylcysteine.&#xD;
      N-acetylcysteine is used as a mucolytic agent in a variety of clinical conditions, such as&#xD;
      acute and chronic bronchitis and cystic fibrosis. The aim of this study, which is performed&#xD;
      in family practices, is to determine the 3-year treatment effects and cost-effectiveness of&#xD;
      oral N-acetylcysteine versus an inhaled corticosteroid (fluticason propionate) in modifying&#xD;
      the course and progression of COPD.&#xD;
&#xD;
      Comparisons: N-acetylcysteine (oral, 600 mg o.d.) and fluticason propionate (dry powder&#xD;
      inhalation, 500 mcg b.i.d.) are compared with placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <completion_date>January 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exacerbations of COPD, condition-specific quality of life</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung function decline, respiratory symptoms</measure>
  </secondary_outcome>
  <enrollment>270</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Lung Diseases, Obstructive</condition>
  <condition>Bronchitis, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 30 and 75 years&#xD;
&#xD;
          -  being a smoker or ex-smoker&#xD;
&#xD;
          -  post-bronchodilator FEV1/FVC ratio is &lt;88% of the predicted value in case of men or&#xD;
             &lt;89% of the predicted value in case of women&#xD;
&#xD;
          -  post-bronchodilator FEV1&gt;=40% and &lt;90% of the predicted value&#xD;
&#xD;
          -  subjects have a GP diagnosis of COPD or had increased cough, sputum and/or dyspnea on&#xD;
             most days for 3 or more months a year, for at least the last 2 years&#xD;
&#xD;
          -  able to provide a written informed consent&#xD;
&#xD;
          -  expected to be able to comply with the study protocol&#xD;
&#xD;
          -  able to communicate with the study personnel and to understand and read instructions&#xD;
&#xD;
          -  females of childbearing potential should use an acceptable method for birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a known history of intolerance or allergy for N-acetylcysteine or fluticason&#xD;
&#xD;
          -  use of long-term oxygen therapy or expected to be in need of oxygen therapy within the&#xD;
             next 3 years&#xD;
&#xD;
          -  registered asthma, allergic rhinitis, and/or allergic eczema as an active problem in&#xD;
             the GPs records within the last 12 months&#xD;
&#xD;
          -  alpha1-antitrypsin deficiency&#xD;
&#xD;
          -  cystic fibrosis&#xD;
&#xD;
          -  active infection due to Mycobacterium tuberculosis&#xD;
&#xD;
          -  status post-lobectomy&#xD;
&#xD;
          -  clinically proven gastric or duodenal ulcer in the previous six months&#xD;
&#xD;
          -  non-compensated severe chronic congestive heart failure&#xD;
&#xD;
          -  life expectancy reduction (e.g. malignancies)&#xD;
&#xD;
          -  evidence of illicit drug use or abuse of alcohol intake&#xD;
&#xD;
          -  expected not to be compliant in taking medications in general&#xD;
&#xD;
          -  being pregnant or giving breastfeeding&#xD;
&#xD;
          -  not complying with the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tjard RJ Schermer, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Centre, Department of Family Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris van Weel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University Nijmegen Medical Centre, Department of Family Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Family Medicine, University of Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Family Medicine, Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.umcn.nl/Pages/default.aspx</url>
    <description>Department of General Practice/Family Medicine, Radboud University Nijmegen Medical Centre</description>
  </link>
  <link>
    <url>http://www.cvz.nl/</url>
    <description>Health Care Insurance Board (CVZ)</description>
  </link>
  <link>
    <url>http://www.astmafonds.nl</url>
    <description>Netherlands Asthma Foundation</description>
  </link>
  <link>
    <url>http://www.igz.nl</url>
    <description>Dutch Health Care Inspectorate</description>
  </link>
  <link>
    <url>http://www.gsk.com</url>
    <description>GlaxoSmithKline (study sponsor)</description>
  </link>
  <link>
    <url>http://www.zambongroup.com</url>
    <description>Zambon Group Spa (Study Sponsor)</description>
  </link>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 11, 2010</last_update_submitted>
  <last_update_submitted_qc>March 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2010</last_update_posted>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Family Practice</keyword>
  <keyword>Respiratory Function Tests</keyword>
  <keyword>Health Status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

